Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
Epigenetics | April 12, 2022 | Volume: 17 | Issue: 12 | Pages: 1715-1725
10.1080/15592294.2022.2058225
| PMID 35412430